Key points from article :
DeepLife, a Paris-based biotech company, has raised $10 million in a Series A funding round to advance its AI-driven platform designed to transform drug discovery and therapeutic development.
Founded in 2019, the company uses AI to create "digital twins" of human cells, allowing for more precise modeling of cellular behavior and drug effects. DeepLife’s innovative platform, Cell Blueprint, is built on multi-omics data, systems biology, and generative AI to help identify molecular triggers that can turn diseased cells back to a healthy state.
Cell Blueprint is at the core of DeepLife's approach, enabling the mapping of cellular networks and providing insights into molecular mechanisms. This technology allows researchers to simulate drug effects on a cellular level, potentially opening doors to therapies for diseases once considered undruggable. The platform has attracted attention from major industry players, with DeepLife’s CEO, Baptista, emphasising its potential to uncover therapies for previously untreatable diseases.
The platform’s capabilities extend across various areas of drug development, including target discovery, biomarker identification, drug repurposing, and understanding complex diseases. By analysing cell-type-specific networks, Cell Blueprint aids in the identification of unique pathways critical for specific cells, improving diagnostic precision and reducing off-target risks. It also sheds light on the mechanisms behind complex diseases, guiding the development of targeted therapies.
The $10 million funding, led by YZR Capital and Relyens Innovation Santé, will allow DeepLife to further refine its digital twin platform and explore applications in autoimmune and neurodegenerative diseases. Experts believe this combination of multi-omics and AI could revolutionise drug discovery and lead to breakthroughs in precision medicine and biomanufacturing.
